Eman M.E. Dokla

434 total citations
22 papers, 334 citations indexed

About

Eman M.E. Dokla is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Eman M.E. Dokla has authored 22 papers receiving a total of 334 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 8 papers in Oncology and 5 papers in Hematology. Recurrent topics in Eman M.E. Dokla's work include Acute Myeloid Leukemia Research (4 papers), Protein Degradation and Inhibitors (4 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Eman M.E. Dokla is often cited by papers focused on Acute Myeloid Leukemia Research (4 papers), Protein Degradation and Inhibitors (4 papers) and Chronic Myeloid Leukemia Treatments (4 papers). Eman M.E. Dokla collaborates with scholars based in Egypt, United States and Taiwan. Eman M.E. Dokla's co-authors include Khaled A. M. Abouzid, Rabah A.T. Serya, Amal Kamal Abdel‐Aziz, Ching‐Shiun Chen, Maha Nasr, Mohamed N. Seleem, Martin J. McPhillie, Nader S. Abutaleb, Saverio Minucci and Christian D. Klein and has published in prestigious journals such as PLoS ONE, Biochemical Pharmacology and European Journal of Medicinal Chemistry.

In The Last Decade

Eman M.E. Dokla

22 papers receiving 326 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eman M.E. Dokla Egypt 9 138 131 41 36 29 22 334
Fereidoon Daryaee United States 12 227 1.6× 94 0.7× 39 1.0× 65 1.8× 38 1.3× 18 463
Alhumaidi B. Alabbas Saudi Arabia 10 152 1.1× 85 0.6× 22 0.5× 38 1.1× 8 0.3× 33 319
Carina Danchik United States 8 183 1.3× 52 0.4× 52 1.3× 62 1.7× 12 0.4× 14 325
Shi Ding China 11 122 0.9× 153 1.2× 37 0.9× 7 0.2× 14 0.5× 38 339
Terence Beghyn France 11 278 2.0× 120 0.9× 64 1.6× 33 0.9× 8 0.3× 15 465
Jingdan Hu United States 10 156 1.1× 120 0.9× 32 0.8× 49 1.4× 36 1.2× 10 416
Kerry E. Murphy-Benenato United States 8 314 2.3× 90 0.7× 35 0.9× 57 1.6× 94 3.2× 9 492
Denis Platel France 11 228 1.7× 41 0.3× 86 2.1× 35 1.0× 66 2.3× 13 430
Kendra R. Vann United States 12 310 2.2× 48 0.4× 73 1.8× 33 0.9× 6 0.2× 20 387
Cornelia J. Forster Germany 11 158 1.1× 111 0.8× 30 0.7× 21 0.6× 4 0.1× 14 311

Countries citing papers authored by Eman M.E. Dokla

Since Specialization
Citations

This map shows the geographic impact of Eman M.E. Dokla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eman M.E. Dokla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eman M.E. Dokla more than expected).

Fields of papers citing papers by Eman M.E. Dokla

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eman M.E. Dokla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eman M.E. Dokla. The network helps show where Eman M.E. Dokla may publish in the future.

Co-authorship network of co-authors of Eman M.E. Dokla

This figure shows the co-authorship network connecting the top 25 collaborators of Eman M.E. Dokla. A scholar is included among the top collaborators of Eman M.E. Dokla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eman M.E. Dokla. Eman M.E. Dokla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bai, Li-Yuan, et al.. (2025). A synthetic molecule targeting STAT3 against human oral squamous cell carcinoma cells. International Journal of Medical Sciences. 22(5). 1081–1091. 2 indexed citations
2.
DeFilippis, RosaAnna, Amal Kamal Abdel‐Aziz, Omar Abou Khaled, et al.. (2025). Structural Optimization and MD Simulation Study of Benzimidazole Derivatives as Potent Mutant FLT3 Kinase Inhibitors Targeting AML. Archiv der Pharmazie. 358(5). e70002–e70002. 2 indexed citations
3.
Dokla, Eman M.E., et al.. (2024). FLT3-PROTACs for combating AML resistance: Analytical overview on chimeric agents developed, challenges, and future perspectives. European Journal of Medicinal Chemistry. 277. 116717–116717. 3 indexed citations
4.
Sharaky, Marwa, Eman M.E. Dokla, & Amal Kamal Abdel‐Aziz. (2024). Anticancer activity of EMD37 against human head and neck cancer: Impact on apoptotic and inflammatory machineries. Toxicology in Vitro. 102. 105967–105967. 1 indexed citations
5.
Abdel‐Aziz, Amal Kamal, Eman M.E. Dokla, Marwa Sharaky, et al.. (2024). Novel sulfonamide-indolinone hybrids targeting mitochondrial respiration of breast cancer cells. European Journal of Medicinal Chemistry. 268. 116255–116255. 8 indexed citations
6.
Abdel‐Aziz, Amal Kamal, et al.. (2023). FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review. Critical Reviews in Oncology/Hematology. 191. 104139–104139. 12 indexed citations
7.
Dokla, Eman M.E., et al.. (2023). Nanoemulgel formulation of a benzimidazole derivative for wound healing. Journal of Drug Delivery Science and Technology. 90. 105121–105121. 7 indexed citations
8.
Abdel‐Aziz, Amal Kamal, Eman M.E. Dokla, Khaled A. M. Abouzid, & Saverio Minucci. (2022). Discovery of EMD37, a 1,2,4-oxadiazole derivative, as a novel endoplasmic reticulum stress inducer with potent anticancer activity. Biochemical Pharmacology. 206. 115316–115316. 9 indexed citations
9.
Dokla, Eman M.E., Nader S. Abutaleb, Maha Nasr, et al.. (2022). SAR investigation and optimization of benzimidazole-based derivatives as antimicrobial agents against Gram-negative bacteria. European Journal of Medicinal Chemistry. 247. 115040–115040. 21 indexed citations
10.
Chu, P., et al.. (2022). Induction of apoptosis using ATN as a novel Yes‐associated protein inhibitor in human oral squamous cell carcinoma cells. Environmental Toxicology. 37(6). 1404–1412. 5 indexed citations
11.
Dokla, Eman M.E., et al.. (2021). Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia. Bioorganic & Medicinal Chemistry. 56. 116596–116596. 18 indexed citations
12.
Dokla, Eman M.E., Amal Kamal Abdel‐Aziz, Amr H. Mahmoud, et al.. (2021). Indolin-2-one derivatives as selective Aurora B kinase inhibitors targeting breast cancer. Bioorganic Chemistry. 117. 105451–105451. 16 indexed citations
13.
Dokla, Eman M.E., et al.. (2020). Penicillin binding protein 2a: An overview and a medicinal chemistry perspective. European Journal of Medicinal Chemistry. 199. 112312–112312. 94 indexed citations
14.
Dokla, Eman M.E., et al.. (2020). Targeting YAP Degradation by a Novel 1,2,4-Oxadiazole Derivative via Restoration of the Function of the Hippo Pathway. ACS Medicinal Chemistry Letters. 11(4). 426–432. 11 indexed citations
15.
Dokla, Eman M.E., et al.. (2019). 1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC. European Journal of Medicinal Chemistry. 182. 111607–111607. 39 indexed citations
16.
Dokla, Eman M.E., Nader S. Abutaleb, Daoyi Li, et al.. (2019). Development of benzimidazole-based derivatives as antimicrobial agents and their synergistic effect with colistin against gram-negative bacteria. European Journal of Medicinal Chemistry. 186. 111850–111850. 56 indexed citations
17.
18.
Weng, Jing‐Ru, et al.. (2018). A 5′ AMP‐Activated Protein Kinase Enzyme Activator, Compound 59, Induces Autophagy and Apoptosis in Human Oral Squamous Cell Carcinoma. Basic & Clinical Pharmacology & Toxicology. 123(1). 21–29. 8 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fereidoon Daryaee Breakdown of academic impact, for papers by Alhumaidi B. Alabbas Breakdown of academic impact, for papers by Carina Danchik Breakdown of academic impact, for papers by Shi Ding Breakdown of academic impact, for papers by Terence Beghyn Breakdown of academic impact, for papers by Jingdan Hu Breakdown of academic impact, for papers by Kerry E. Murphy-Benenato Breakdown of academic impact, for papers by Denis Platel Breakdown of academic impact, for papers by Kendra R. Vann Breakdown of academic impact, for papers by Cornelia J. Forster
Rankless by CCL
2026